BPA for ocaliva
Ended Awarded Last action
- Contract number
- 36E79725A0001
- Awardee
-
Intercept Pharmaceuticals Inc. UEI GHNKCLBJRMK7
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $21,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This single-award Blanket Purchase Agreement was established between the Department of Veterans Affairs National Acquisition Center and Intercept Pharmaceuticals Inc. for the supply of Ocaliva (obeticholic acid) tablets under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract, awarded on October 17, 2024, carries a ceiling value of $21,000,000 with an ultimate completion date of October 3, 2025. No set-asides were utilized in this procurement. Intercept Pharmaceuticals Inc. serves as the sole awardee and will provide Ocaliva 5mg tablets to fulfill the treatment needs of veterans suffering from primary biliary cholangitis, a chronic liver disease. The product is specifically indicated for use in combination with ursodeoxycholic acid for veterans who demonstrate an inadequate response to ursodeoxycholic acid therapy alone.
The Department of Veterans Affairs established this indefinite delivery vehicle to ensure efficient and timely procurement of Ocaliva for eligible veteran populations across its healthcare systems. However, the contract description notes that this BPA has been cancelled due to product withdrawal from the United States market, indicating that Intercept Pharmaceuticals Inc. has discontinued commercial availability of Ocaliva domestically. This cancellation represents a significant change in the department's ability to procure this pharmaceutical treatment modality for affected veterans and may necessitate identification of alternative therapeutic options or treatment protocols for patients previously managed with this medication.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0001?
36E79725A0001 was awarded to Intercept Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on October 17, 2024.
How much is contract 36E79725A0001 worth?
36E79725A0001's own ceiling is $21,000,000.
Who can order from contract 36E79725A0001?
36E79725A0001 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0001 under another contract?
Yes. 36E79725A0001 is a blanket purchase agreement under 36F79724D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0001 competed?
The extent of competition for 36E79725A0001 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV